Sigma-Aldrich Corp

Sigma-Aldrich — Investor Day (March 2010)

141 slides from Sigma-Aldrich's investor day presentation, Mar 16, 2010

  1. Slide 1: Sigma-Aldrich Corporation: Enabling Science to Improve the Quality of Life

    Sigma-Aldrich Corporation Enabling Science to Improve the Quality of Life March 16, 2010 Exhibit 99.1

  2. Slide 2: Cautionary Statement

    • Our presentation today will include forward looking statements r elating to the Company ’ s future performance, goals, strategic actions • With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency - adjusted growth, and • Management reports both GAAP and

  3. Slide 3: Jai Nagarkatti, Chairman, President and CEO

    Sigma-Aldrich Corporation Jai Nagarkatti Chairman, President and Chief Executive Officer

  4. Slide 4: Agenda

    Enabling science to improve the quality of life Agenda Summary Growth Drivers Portfolio Assessment and Financial Roadmap Our Overarching Objective / Plan Overview

  5. Slide 5: Our Overarching Objective

    To build on our core capabilities and leverage our financial strength to deliver sustainable above-market growth and create value for our Employees, Customers and Shareholders Our Overarching Objective

  6. Slide 6: Overview

    Overview How should you measure success? Plan to achieve our objective Our markets and global trends Who is Sigma-Aldrich?

  7. Slide 7: Delivering Value Through a Diversified Portfolio

    Sigma-Aldrich ($ Million) 2009 Revenue $2,148 2009 EBITDA $ 592 2009 Free Cash Flow $ 396 Delivering strong financial performance despite a challenging economy Who is Sigma-Aldrich? Delivering Value Through a Diversified Portfolio

  8. Slide 8: Who is Sigma-Aldrich?

    70% Research Consumables 30% Fine Chemicals & Services • Research Business • Manufacturing (SAFC) A Life Science company enabling researchers and manufacturers to improve the quality of life Who is Sigma-Aldrich? • Customers – Academia – Pharma & Biotech – Industrial – Hospitals – Testing Labs • Pro

  9. Slide 9: Markets and Global Trends

    Sigma-Aldrich participates in space with significant room for growth Markets and Global Trends Markets

  10. Slide 10: Global Economy Shifting East

    Sigma-Aldrich’s plan to capture opportunity: expand presence in emerging markets Markets and Global Trends Global Economy Shifting East *As determined by FTSE Global Equity Index; Source: Global Insight's World Overview Projected GDP Growth GDP in $ Trillions

  11. Slide 11: Shift Towards Biology

    Sigma-Aldrich’s plan to capture opportunity: build reputation through innovation in Biology Market and Global Trends Shift Towards Biology Pharmaceutical R&D Increasingly Focused on Biologics

  12. Slide 12: Exponential Importance of the Internet

    Sigma-Aldrich’s plan to capture opportunity: Aggressive investment to enhance customer experience Market and Global Trends Exponential Importance of the Internet *World Internet Stats Internet Users Have Increased by Nearly 10 Times in the Past Decade*

  13. Slide 13: Focus on Energy, the Environment and Food Safety

    Sigma-Aldrich’s plan to capture opportunity: focused approach in Analytical, Chemistry and Materials Science to support research and manufacturing Market and Global Trends Focus on Energy, the Environment and Food Safety Global Renewable Energy Growth 2008-2018 ($ Billions)

  14. Slide 14: Plan to Achieve Objective

    above-market growth and create value for our employees, customers and shareholders To build on our core capabilities and leverage our financial strength to deliver sustainable Plan to Achieve Objective Approach • Site Consolidation Revitalize or divest underperforming assets Redeploy ABC M = Focus o

  15. Slide 15: Initiatives Leverage Competitive Advantage

    Initiatives Leverage Competitive Advantage Leverage core competencies through targeted initiatives to create value Plan to Achieve Objective • Share repurchase Capital structure Financial strength • Competitive pricing strategy Pricing Sourcing knowledge • Optimize Supply Chain • Leverage Process Im

  16. Slide 16: Impact of Top Line Growth Initiatives

    4% Incremental contribution to top line growth Incremental Impact Initiatives Plan to Achieve Objective Impact of Top Line Growth Initiatives 0.5% Expand Web and B2B capabilities Realign sales effort Optimize Go-to-Market 1.0% Apply our technologies to customers’ unique and evolving supply chains SA

  17. Slide 17: M&A activity will supplement organic growth

    M&A activity will supplement organic growth ABC M Targets High Growth Markets Sigma-Aldrich Market Share

  18. Slide 18: Five-Year Financial Targets

    Strategic actions build sustainable value Incremental Impact Five-Year Financial Targets How to Measure Success 200-300 bpts Expand cumulative operating margins by 2014 > $2 Billion Free cash flow (five years) 7-8% Top line organic growth (normal economic conditions)

  19. Slide 19: Management Team

    Management Team

  20. Slide 20: Portfolio Assessment and Financial Roadmap

    Portfolio Assessment and Financial Roadmap Rakesh Sachdev Sr. Vice President, Chief Financial Officer and Chief Administrative Officer

  21. Slide 21: Outline

    Outline Capital Structure and Use of Cash Investment Thesis Looking Ahead – Sales Growth Drivers – Profitability Drivers Portfolio Assessment Historical Performance and Trends 2009 Results Recap and 2010 Guidance

  22. Slide 22: 2009 Key Business Highlights

    2009 – Key Business Highlights • Strong financial year, despite economic environment – Several records achieved – EPS & Free Cash Flow • Research Biotech growth driven by – Innovative new antibody products – Regenerative medicine – Epigenetic products • Fine Chemicals (SAFC) benefited from sale of c

  23. Slide 23: Full Year 2009 Financial Results

    2009 Performance drove EPS and free cash flow to a new record. Free cash flow improvement driven by $70M reduction in inventory Full Year 2009 Financial Results

  24. Slide 24: Pre-tax Margin Improved in 2009

    2009 pre-tax margins improved 60 bpts despite currency headwinds and restructuring charges Pre-tax Margin Improved in 2009

  25. Slide 25: 2010 Guidance

    Organic Revenue Growth Mid single digits Reported EPS $3.00 to $3.15 Free Cash Flow > $350 million SIGMA-ALDRICH’

  26. Slide 26: Historical Trends: Profitable Sales Growth

    Continued a 35 year track record in EPS growth Historical Trends – Profitable Sales Growth • Demonstrated historic performance • Robust business model – even in a downturn

  27. Slide 27: Historical Performance: Shareholder Returns

    • Share Price Consistently achieving high ROE. Share price has outperformed the peer and broad market indices Historical Performance – Shareholder Returns

  28. Slide 28: Sigma-Aldrich Portfolio Snapshot

    ~50% of research business comes from biology products and services Sigma-Aldrich Portfolio Snapshot Mapping Old With New Biology focus in Research Markets *Estimated

  29. Slide 29: Portfolio Snapshot: Another Look

    Portfolio Snapshot Another Look

  30. Slide 30: Research Portfolio: Well-positioned for Growth

    Financial Impact Addressable Market Characteristics Research Portfolio Significant opportunities in $17 billion addressable market Research Portfolio Well-positioned for Growth (~70% of Total Company) • Lower growth (~5%) • Stable profitable business $7.4B • Broad offering of 18,000 products • Basic

  31. Slide 31: SAFC Portfolio Positioned for Value Creation

    Financial Impact Characteristics SAFC Portfolio Significant opportunities in $60+ billion addressable market SAFC Portfolio Positioned for Value Creation (~30% of Total Company) • Asia growth • Benefit from global recovery • Diverse applications – LED lights, LCDs, semiconductors, solar panels Hitec

  32. Slide 32: Sales Growth: Where?

    Sales Growth – Where? Above Avera g e Market Growth

  33. Slide 33: Sales Growth: How?

    Sales Growth – How? Initiatives to achieve above market g rowth rates

  34. Slide 34: Profitability Drivers

    Net 200-300 basis point improvement in operating margin over 5 years Profitability Drivers

  35. Slide 35: Restructuring Activities

    Recently Announced Actions Activities Will drive margin expansion Restructuring Activities Selective reduction in workforce Voluntary early retirement program Improve customer service levels Exiting five manufacturing sites in U.S. and Europe Total one-time costs of actions estimated at $31 million,

  36. Slide 36: Capital Structure

    Solid liquidity position to fund growth Capital Structure (At December 31, 2009)

  37. Slide 37: Historical Use of Cash (2005 to 2009)

    $ Billions Over $1 billion returned to shareholders through share buy-back and dividends Historical Use of Cash (2005 to 2009) Uses $(0.3) Net 0.3 Dividends 0.9 Share buy-back $ 0.6 Acquisitions/Investments $ 1.5 Free cash flow 0.5 Capital expenditures $ 2.0 Operating cash flow Funded with debt

  38. Slide 38: Future Uses of Cash

    Expect free cash flow to be in excess of $2 billion over next five years Future Uses of Cash 2010 and Beyond • Fund organic growth through technology, partnerships, licensing and go-to-market investments • Fund inorganic growth • Cash dividends • Share repurchases • Debt reduction

  39. Slide 39: Inorganic Opportunities

    Inorganic Opportunities Adds to Overall (Licenses, Partnerships, SIAL Growth JVs, Acquisitions) aie PP . Strategic Filter Financial Filter * Product/Technology Expansion * Exceed Overall Financial Target ~ Analytical - Sales Growth >10% - Biology - ROI ~20% - Materials Science * Product and Distribu

  40. Slide 40: Investment Thesis: Why Sigma-Aldrich Now?

    Value Creation Si g ma-Aldrich Advanta g e Investment Thesis Why Sigma-Aldrich Now? • Manufacturing and distribution footprint optimization • Demonstrated ability to achieve earnings and cash flow savings from global supply chain and process improvement initiatives • Margin expansion from profitable

  41. Slide 41: Analytical

    Analytical Frank Wicks President, Research Essentials/ Research Specialties

  42. Slide 42: Analytical Chemistry Is

    Platform recognized for its innovation and breadth Analytical Chemistry Is: The study of the chemical/biochemical composition of matter It asks and answers three fundamental questions: • What is the material present? • How much is present? • What is the quality?

  43. Slide 43: Typical Analytical Process

    Sample Induction Sample Collection Sample Preparation (Separation) Detection Data Collection and Analysis Typical Analytical Process Material to be Analyzed Analyzer System Results

  44. Slide 44: Important Questions Answered by Analytical

    Important Questions Answered by Analytical • How do the manufacturers of your multi-vitamin tablets know they contain the right amounts of the right vitamins? How do they know the tablets don’t degrade or spoil? – Analytical Chemistry • How do researchers know if they have synthesized the right chem

  45. Slide 45: How Analytical Fits Within Our Research Growth Strategy

    How Analytical Fits Within Our Research Business Growth Strategy ABC M Our customers use analytical technology combined with chemistry, biology and/or materials science in all stages of their workflow from “Discover to Apply”

  46. Slide 46: Analytical Market Overview

    Market growth of 5% Analytical Market Overview * Source: SDI, Analyst Reports, Team Analysis * Includes instruments (HPLC, GC, TLC, LPLC, IC, flash chromatography), consumables, standards and reagents Market by Product Type

  47. Slide 47: Global Analytical Market Overview

    • Market by customer segment Global Analytical Market * Overview • Environmental – Testing pollutants in water, air and soil • Biotech – Sample prep and analysis of large bio-molecules, bio-markers, etc. • Food & Beverages – Testing nutrients, ingredients, additives and impurities • Pharmaceutical –

  48. Slide 48: Analytical Innovative Solutions

    • Hydranal • SPME • dSPE • Ascentis Improving the quality of life Analytical Innovative Solutions For Environmental, Food Safety and Pharmaceutical Testing ® • The “gold standard” for water content testing • Positively impacts environment by reducing chemicals required for analytical testing • Facil

  49. Slide 49: Analytical Growth Strategy

    Expanding analytical innovation Analytical Growth Strategy • Become the “Aldrich” of analytical standards and reagents • Chemical analysis – Increased emphasis in food safety and the environment • Additional capability for collaborative innovation with academia and industry – Increased R&D and busin

  50. Slide 50: Going Forward

    Going Forward To achieve >10% top-line sales growth, we will become the leading provider of analytical consumables and know-how • Known as “the source” for the highest quality analytical consumables • The commercial partner-of-choice for analytical consumable innovators • A valued, sought-after prob

  51. Slide 51: Chemistry

    Chemistry Frank Wicks President, Research Essentials/ Research Specialties

  52. Slide 52: Chemistry Is

    Chemistry Is: The science of matter and the changes it undergoes Sigma-Aldrich – “Organic molecules used in scientific research”

  53. Slide 53: Chemistry Market Overview

    Market growth 2 - 3% Market Overview • $1B in size • The users are most often the buyers • Main segments are Pharma, Biopharma, Academia, Industrial • Pharma segment hard hit by consolidation of the industry, trend towards big molecules and general cost savings in R&D • Academia and governmental seg

  54. Slide 54: Materials Science is a fast growing market segment

    Materials Science is a fast growing market segment Chemistry • Chemical Synthesis – most comprehensive product range of simple molecules to enable creation of more complex molecules • Organic Building Blocks – basic molecules used especially in drug discovery • Stable Isotopes – isotopically labeled

  55. Slide 55: Chemistry Growth Strategy

    We will deliver 3 - 4% growth Chemistry Growth Strategy • Aldrich is the premier brand with 40% market share • Broadest selection of 50,000 products – add 1,000 new annually • Sales channels – mainly catalog and e-channels • One-half million catalogs distributed • Aldrichimica Acta – leading organic

  56. Slide 56: Materials Science

    Materials Science Frank Wicks President, Research Essentials/ Research Specialties

  57. Slide 57: Materials Science Is

    Materials Science Is: A field of study that focuses on specific groups of materials with particular properties of high technological value and their applications towards devices

  58. Slide 58: How Materials Science Fits Within Chemistry Growth Strategy

    How Materials Science Fits Within Sigma-Aldrich’s Chemistry Growth Strategy • Chemical knowledge for Life Science applications carries over to high technology • Faster growing applications area – capturing flat panel displays, environmental • Over the past 6 years we have: – Positioned the Aldrich b

  59. Slide 59: Materials Science Market Overview

    Development market twice the size of research market Key Drivers Macro Trends • • • Materials Science Market Overview Global Materials Science R&D Market • $0.5 billion • Competition is fragmented • Market growth – 9% – Big and growing in size and diversity – Funding intact – Our target markets are

  60. Slide 60: Materials Science Growth Strategy

    Reach non-traditional customers Materials Science Growth Strategy Use innovation focused approach to fill the gaps: • Accelerate new product introduction on existing platforms • Create new offerings for development customers • Enhance analytical capabilities • Polymers • Metals • Ceramics Expand our

  61. Slide 61: Materials Science: Going Forward

    • Objective: > 10% growth • Scope: • Key Growth Strategies Deliver > 10% growth Going Forward • To supply high quality materials and services to scientists and engineers engaged in fundamental and applied materials science research worldwide and in the development of innovative products in select ma

  62. Slide 62: Biology

    Biology David Smoller President, Research Biotech

  63. Slide 63: Biology Is

    • A natural science concerned with the • Challenge Biology Is: study of life and living organisms • Understanding the dynamics of the complex biological pathways and molecular interactions within living cells

  64. Slide 64: Biology Segments

    Comprehensive portfolio of life science products – $800 million Biology Segments

  65. Slide 65: How Biology Fits within Research Growth Strategy

    How Biology Fits within our Research Business Growth Strategy • Biology is a complimentary technology to chemistry in the life science workflow from “Discovery to Drug” • Life science research moving towards understanding complex biological pathways and entire biological systems • R&D grants awarded

  66. Slide 66: Biochemistry / Biology Market

    Business Unit Market Size ($ Millions) Market Growth Biochemistry / Biology Market Biomolecules RB $1,900 9% Functional Genomics RB Cells & Cell Based Assays RB Protein Assays RB Transgenics & Services RB 2,000 Genomics RB 1,800 Cell Culture RE/RS Specialty Biochem and Enzymes RE/RS Lab Essentials R

  67. Slide 67: Sigma is Where Bio Begins

    Sigma is “Where Bio Begins” for our Customers

  68. Slide 68: Biology Segments

    Comprehensive portfolio of life science products – $800 million Biology Segments

  69. Slide 69: Largest Breadth of Traditional Biochemistry Products

    Basic tools for Biochemical research Largest Breadth of Traditional Biochemistry Products • Offer over 18,000 products • Add 500 new products each year to support the latest cutting edge research • Largely sold through the catalog and e-channels – Over one-half million catalogs distributed • Over on

  70. Slide 70: Largest Breadth of Traditional Biochemistry Products

    Will deliver 5% growth annually Largest Breadth of Traditional Biochemistry Products • Cell Culture – Complete range of media and components to grow a variety of cell types • Specialty Biochem and Enzymes – Industry leading offering of products for basic Biochemical research • Lab Essentials – Broad

  71. Slide 71: Biology Segments

    Comprehensive portfolio of life science products – $800 million Biology Segments

  72. Slide 72: Biologically Rich Content Products

    Biologically rich content products Leading Biomolecule Provider Biological Rich Content • Leading biomolecule supplier with 4,000 bioactive small molecules and thousands of proteins and peptides used for life science research • Number one oligo synthesis world-wide with manufacturing in all regions

  73. Slide 73: Functional Genomics and Regenerative Medicine

    Leading the Industry Functional Genomics and Regenerative Medicine • Unparalleled gene editing technology – CompoZr™ Zinc Finger Nucleases (ZFN) • Cutting-edge gene silencing products – Mission ® siRNAs and the largest set of validated lentivirus based shRNA clones • Innovative set of reagents for r

  74. Slide 74: New Paradigm in Animal Models

    New Paradigm in Animal Models • Most relevant model system for your research – Rat – Mouse – Other • Addresses currently unmet needs – ADME – CNS disease – CV disease – Hypertension – Immunodeficiency models – Increased productivity Sigma Publishes in Science on the First KO Rat

  75. Slide 75: Sigma Acquires Ace Animals, Inc.

    Sigma Acquires Ace Animals, Inc. • High quality research rodents to the biomedical industry since 1973 • Brings rodent breeding and distribution capabilities and marries them to our SAGE™ Labs animal creation business

  76. Slide 76: Leveraged ZFNs in Cell-based Assays

    ZFNs used to label organelles in a living cell Leveraged ZFNs in Cell-based Assays

  77. Slide 77: Power of ZFNs in Stem Cell Research

    Power of ZFNs in Stem Cell Research YFP + Pluripotent Stem Cells

  78. Slide 78: Connecting with Scientists

    Connecting with Scientist Information and Social Networking

  79. Slide 79: Biology: Going Forward

    Sigma is the only company that is positioned to do this Going Forward • To achieve double-digit top line sales growth – become leader in specific market segments within the cell biology market and differentiated animal models market by: – Acquiring new biologically rich content products – Leverage p

  80. Slide 80: Biology Segments Growth

    Overall growth >7% Biology Segments 5% Growth >10% Growth

  81. Slide 81: Go To Market

    Go To Market Gerrit van den Dool Vice President, Sales

  82. Slide 82: Customer Profiles

    • • • • Different customer types “My reps should bring me new ideas; updated equipment and reagents - that is really helpful.” -Biologist “What I really like about my rep is the ability to call someone when I have problems and know that they will fight to get my problem resolved.” -Enterprise Resear

  83. Slide 83: Coverage Strategies

    Varied customers require different approaches Go To Market Coverage Strategies Initiatives

  84. Slide 84: Biologists require higher touch

    Biologists require higher touch Go To Market Adjustments • Biologists require higher touch • Realign sales force to achieve more focused coverage • No substantial change in total sales force Level of “Optimal” Rep Interaction 1 Contact preference of at least once every 1-6 months 2 Contact preferenc

  85. Slide 85: Strategic Accounts

    Customized approach for global customers Go To Market Strategic Accounts Coordinate efforts across Research and SAFC for Biopharma customers at this level Coordinate efforts across all segments at this level Specialized management level personnel to cover Global accounts

  86. Slide 86: SAFC

    SAFC Gilles Cottier President, SAFC

  87. Slide 87: SAFC Is

    Unique manufacturing capabilities for Life Science and High Technology commercial applications SAFC Is:

  88. Slide 88: SAFC Capabilities and Supply Solutions

    Complex custom development ‘Small molecule API and biologics High potency and viral particles Technical expertise and project management Critical raw materials for cell culture manufacturing Raw materials characterization Custom media development and services Cell line engineering with ZFN technolog

  89. Slide 89: Leverages Our Research Business

    Leverages Our Research Business • Leverage research assets • Utilize our scientific knowledge • Leverage same customer base from research to commercial applications

  90. Slide 90: SAFC Market Size and Growth

    SAFC Supply Solutions SAFC Pharma SAFC. Biosciences SAFC Hitech ial Raw Materials terials Diagnostic Raw Materials Flavors & Fragrances General API's & Pharma Intermediates Generic API's Biologics API's Biopharma Raw Materials, Chemicals for Silicon & ‘Compound Semiconductors Chemicals for Solar Ene

  91. Slide 91: Unique Manufacturing Capabilities

    Enabling science to improve the quality of life Unique Manufacturing Capabilities Application Examples of Our Technologies • Late phase Antibody Drug Conjugates (ADCs) and viral products for various cancer treatments • Adjuvants and critical raw materials for vaccines • High purity compounds for Lig

  92. Slide 92: SAFC Project Pipeline

    Pipeline getting stronger SAFC Project Pipeline Pharmaceuticals and Biopharmaceuticals

  93. Slide 93: SAFC Strategy

    SAFC Strategy • Pursue selective commercial opportunities utilizing distinctive technologies and competencies which leverage our scientific knowledge and allow us to maximize our return • Get closer to large life science customers with comprehensive capabilities offer • Leverage quality leadership p

  94. Slide 94: SAFC Growth Initiatives and Unique Manufacturing Capabilities

    $100 million additional sales within next three years SAFC Growth Initiatives and Unique Manufacturing Capabilities • Cell lines engineering with Zinc Finger Nuclease (ZFN) for commercial therapeutic protein production • High Potency Active Pharmaceutical Ingredient (HPAPI) and viral particles for c

  95. Slide 95: Cell Line Engineering with ZFN Technology: Market Dynamics

    Cell line engineering enable significant improvement in productivity and reliability of commercial therapeutic protein production Cell Line Engineering with ZFN Technology Market Dynamics Pharmaceutical Biologics • Has become an established production process in biological pharmaceutical production

  96. Slide 96: Cell Line Engineering with ZFN Technology

    • Unique Capabilities and Benefits Acquired exclusive rights for ZFN technology for bioproduction systems in October 2009 Cell Line Engineering with ZFN Technology • ZFN versus traditional cell line engineering approach – Cut cell line development time by 50% (six months versus 12 months) – Ability

  97. Slide 97: Cell Line Engineering with ZFN Technology

    Cell Line Engineering with ZFN Technology

  98. Slide 98: HPAPI and Viral Particles for Oncology/Vaccine

    Oncology is becoming number one therapeutic area HPAPI and Viral Particles for Oncology/Vaccine Technology Trends • Increasing complexity and potency of drugs • Monoclonal antibodies to reach and react with cancer specific tissue • Blend technologies to achieve targeted and specified results • Vacci

  99. Slide 99: HPAPI and Viral Particles: Technology Investment

    • Technology Investment Investment of over $90 million in the last three years, expanding ‘technology solutions’ throughout the drug development lifecycle HPAPI and Viral Particles for Oncology/Vaccine

  100. Slide 100: HPAPI and Viral Particles: Unique Manufacturing Capabilities

    • Unique Manufacturing Capabilities Leadership position = Double digit growth for these technologies in 2009 HPAPI and Viral Particles for Oncology/Vaccine • World leader for high potent active pharmaceutical ingredient production • Largest and leading CMO for production of viral vectors • Leading c

  101. Slide 101: Compound Semiconductors for LED: Market Dynamics

    Lighting will undergo the same upheaval as the film and music business Compound Semiconductors for LED Market Dynamics Source: Phillips Lighting 2009 Source: ‘LED LCD TV Roadmap and Market Forecast by Maker’ December 2009, Displaybank Global LED LCD TV Market Forecast General Illumination Market

  102. Slide 102: Compound Semiconductors for LED

    Well positioned to capture market explosive growth • Unique Capabilities Compound Semiconductors for LED • SAFC Hitech – leader in manufacturing and distributing key metal organics for the LED Market – Trimethyl Gallium, Trimethyl Indium, Triethyl Gallium, Trimetyl Aluminium • Global manufacturing f

  103. Slide 103: SAFC: Going Forward

    • Our Key Growth Initiatives SAFC objective > 7% growth Going Forward • Well positioned to respond to fast growing end-markets • Balanced portfolio between innovative technologies and traditional capabilities • Aligned to mega-trends – Shift from chemistry towards biology – Increasing complexity and

  104. Slide 104: Geographic Expansion

    Geographic Expansion Eric Green Vice President and Managing Director, International

  105. Slide 105: Emerging markets have significant growth potential

    Emerging markets have significant growth potential Market Drivers and Trends • Emerging markets will represent 43% of global GDP by 2018 • Developing countries aggressively boosting R&D funding • Pharmaceutical companies increasingly rely on off-shoring and out-sourcing • Local companies are emergin

  106. Slide 106: International Markets (Asia Pacific and Latin America)

    • • Direct presence in 14 International countries International Markets (Asia Pacific and Latin America) Mexico Brazil Argentina Chile 10% 90% South Korea Japan China Taiwan Vietnam Malaysia India Singapore Australia New Zealand

  107. Slide 107: Strong Performance In International Markets

    Emerging regions playing larger role Strong Performance In International Markets

  108. Slide 108: Current International Profile

    Current International Profile

  109. Slide 109: Key Growth Drivers

    Key Growth Drivers

  110. Slide 110: Go-To-Market

    Country specific modes of customer interaction remain essential • Expand sales force coverage • Optimize pricing strategy • Drive e - adoption Go-To-Market • Invest in technical selling to support ABC M strategy • Extend reach into new geographies • Invest in web localization • “Ease of Use” is our

  111. Slide 111: Infrastructure Expansion

    Infrastructure remains a key differentiator as we drive demand • • • Infrastructure Expansion Expand distribution capabilities • Existing geographies • New geographies Continue to differentiate through service • Optimize inventory management Adapt our logistics capabilities to support new product li

  112. Slide 112: Localization of Supply

    Increase share and margins through local sourcing Localization of Supply • Qualify and develop in-country sources for selected product categories • Invest in local QC and packaging infrastructure • Leverage in-country sources through global supply chain integration * Sigma-Aldrich Estimate Laborator

  113. Slide 113: Acquisitions and Partnerships

    Bolt-on acquisitions targeted to support ABC growth in international M Acquisitions and Partnerships • Increase emphasis on targeting inorganic growth opportunities in the region • Form strategic partnerships with local and global companies • Identify technologies and capabilities to support ABC M s

  114. Slide 114: Conclusion and Summary

    To achieve 30% of corporate sales by 2014 Conclusion and Summary • We have a sustainable growth strategy • The growth trend for emerging markets remains strong • We are investing in strategic capabilities while focusing on selling and supply chain • We will seek to supplement our organic growth with

  115. Slide 115: eBusiness

    eBusiness Amanda Halford Vice President, eBusiness

  116. Slide 116: Our Vision

    “I firmly believe that companies that win the battle of e-commerce will win the war in our competitive environment.” Jai Nagarkatti, October 2009 Our Vision Transition from a “catalog” company with a website to a “web” enabled company with a catalog • Drive our ABC M strategy through Internet leader

  117. Slide 117: Fastest Growing Channel to Market

    • Key eBusiness is a key driver for overall growth Fastest Growing Channel to Market Will Accelerate Growth Statistics – • 45% of global research sales vs. 4% in 2000 • 54% of U.S. research sales vs. 7% in 2000 • 3 million monthly visits vs. 600k in 2000 $700 M through the web in 2009

  118. Slide 118: Opportunities at Each Stage of Online Buying Cycle

    Opportunities to Drive Revenue at Each Stage of the Online Customer Buying Cycle Learn Choose Use

  119. Slide 119: Largest Channel to Market

    Largest Channel to Market Driving Strategy As our single largest channel to market, our website will drive our ABC M strategy Segmentation

  120. Slide 120: Customer Insight

    Customer Insight Creating a Differentiated Customer Experience • Observes customers in their work environment • Watches how they actually work, not just listening to what they say they do • Translates observations into functionality that enhances customer’s experience Localization Personalization

  121. Slide 121: New Technologies

    New Technologies Accelerated Access to Our Unrivalled Scientific Knowledge

  122. Slide 122: Did You Know?

    • Number of internet devices by year Did You Know? • 1984 – 1,000 • 1992 – 1,000,000 • 2008 – 1,000,000,000

  123. Slide 123: Growing Online Market

    Growing Online Market Accelerating Revenue Growth As a Web-enabled company, we will take full advantage of the growing online market to accelerate revenue growth

  124. Slide 124: Global Supply Chain

    Global Supply Chain Dave Julien President, Global Supply Chain

  125. Slide 125: Sigma-Aldrich Global Supply Chain 2010 and Beyond

    An integrated effort Sigma-Aldrich Global Supply Chain 2010 and Beyond Manufacturing Distribution/Logistics Quality Control Centers of Excellence Product Portfolio Management Packaging Procurement Planning

  126. Slide 126: Global Supply Chain Project Goals

    • Global Integration • People • Processes Faster, better and more cost-effective Global Supply Chain Project Goals – • Organization • Supply Chain governance • Metrics • Systems (SAP) • New capabilities and expertise • Complexity reduction • Flexibility • Risk reduction

  127. Slide 127: Global Supply Chain Progress

    • Procurement and planning • Manufacturing, QC and packaging • Product portfolio • Logistics and distribution • Systems and harmonization Teams formed and projects active Global Supply Chain Progress – • Global organization • Harmonizing, global teams • Eliminating overlaps • Global management • Pro

  128. Slide 128: Global Supply Chain 2009 Results

    • 2009 Results Pulled projects forward in 2009, beat targets Global Supply Chain • Inventory Reduction From 7.0 to 6.5 MOH ($75M) • Supply Chain Savings Net $22 Million • Process Improvement Savings $15 Million • Procurement 75% of Total Savings • Service > 90% Available Globally

  129. Slide 129: Global Supply Chain 2010 Targets

    • 2010 Targets 2010 targets similar to 2009 Global Supply Chain • Inventory Reduction < 6.5 MOH • Supply Chain Savings Net $15 Million • Process Improvement Savings $15 Million • Service Rates Maintained or improved from 2009 • Systems SAP installations to be completed at major sites

  130. Slide 130: Procurement 2010 Goals

    Procurement still largest opportunity Global Supply Chain Procurement – 2010 Goals • Total spend greater than $1 Billion – 50% direct / 50% indirect • Almost a decade into initiative; increased focus 2007 – $110 Million plus saved • Sigma-Aldrich procurement controls 55%, target 80% • Continued focu

  131. Slide 131: Procurement savings hitting peak

    Procurement savings hitting peak Global Supply Chain Procurement 2010 Supply Chain Project

  132. Slide 132: Planning 2010 Goals

    Decreased inventory by $100+ million while improving fill rates Global Supply Chain Planning – 2010 Goals • Priority planning for new products • Special focus on fastest selling products • Implementing advanced planning system tools • Continued emphasis on reducing inventory write-offs • Reducing cy

  133. Slide 133: Manufacturing, QC and Packaging

    Global strategy developing Global Supply Chain Manufacturing, QC and Packaging – • Active global teams developing 5-year strategies • Facilities optimization – centers of excellence – capacity utilization – regional requirements • Packaging component consolidation ($60M spend) • Process, testing and

  134. Slide 134: Distribution Initiative: Customer Focus

    Customized solutions to drive sales Global Supply Chain Distribution Initiative – Customer Focus – • High stock availability – 96% for U.S. and Europe – 80% for China and India • 24-hour service to the key markets • Highly automated distributon center in Europe • Excellence in handling chemicals • G

  135. Slide 135: Distribution Initiative: Capacity

    8 million units in stock to support our customers Global Supply Chain Distribution Initiative – Capacity SD Mke StL

  136. Slide 136: Distribution Initiative: Significant contribution to savings

    Significant contribution to savings Global Supply Chain Distribution Initiative – • Global harmonized processes to improve efficiency • Inventory optimization through global management • Continuous improvement to global network • Development of customized solutions • Optimize regional centers • Expa

  137. Slide 137: Supply Chain Pre-tax Savings

    Ahead of plan, potential to beat targets Global Supply Chain Pre-tax Savings 2% pretax margin improvement by 2014 Supply Chain Expected Savings

  138. Slide 138: Summary

    Summary Jai Nagarkatti Chairman, President and Chief Executive Officer

  139. Slide 139: Compelling investment opportunity

    Compelling investment opportunity Sigma-Aldrich Uniquely Positioned for Value Creation History of profitable growth Strong financial position and cash flow Plans to enhance growth rates and improve profitability Diversified portfolio: products, customers, geography Unrivaled scientific knowledge and

  140. Slide 140: Summary: Why Sigma-Aldrich Now?

    Value Creation Sigma-Aldrich Advantage Summary Why Sigma-Aldrich Now? • Manufacturing and distribution footprint optimization • Demonstrated ability to achieve earnings and cash flow savings from global supply chain and process improvement initiatives • Margin expansion from profitable sales growth

  141. Slide 141: Questions?

    Questions? Call the conference telephone number Toll free: 877-660-8922 Access code: 4999095 Sigma-Aldrich Corporation

Sigma-Aldrich — Investor Day (March 2010) on 6ix